Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

John J.V. McMurray(University of Glasgow), Anna-Maria Langkilde(AstraZeneca (Finland)), Silvio E. Inzucchi(Yale University), Inder S. Anand(University of Minnesota), Kieran F. Docherty(British Heart Foundation), Michael Böhm(Saarland University), Mark C. Petrie(British Heart Foundation), Piotr Ponikowski(Wroclaw Medical University), Pardeep S. Jhund(Copenhagen University Hospital), Olof Bengtsson(Copenhagen University Hospital), Eileen O’Meara(Montreal Heart Institute), Marc S. Sabatine(Brigham and Women's Hospital), Mikaela Sjöstrand(Copenhagen University Hospital), Rudolf A. de Boer(Erasmus MC), Lars Køber(University of Copenhagen), Felipe A. Martínez(Universidad Nacional de Córdoba), С. Н. Терещенко(Copenhagen University Hospital), Jarosław Dróżdż(Copenhagen University Hospital), Charlotta Ljungman(Swedish Academy), David L. DeMets(University of Wisconsin–Madison), Jan Bělohlávek(Charles University), Mirta Díez(Copenhagen University Hospital), Mikhail Kosiborod(AstraZeneca (Brazil)), Scott D. Solomon(Brigham and Women's Hospital), Pham Nguyễn Vinh(Copenhagen University Hospital), Tzvetana Katova(Copenhagen University Hospital), Vijay Chopra(Max Super Speciality Hospital), Masafumi Kitakaze(Hanwa Memorial Hospital), Subodh Verma(St. Michael's Hospital), Chern‐En Chiang(National Yang Ming Chiao Tung University), Béla Merkely(Semmelweis University), Claes Held(Uppsala University), Morten Schou(Copenhagen University Hospital), Junbo Ge(Shanghai Medical College of Fudan University), Akshay S. Desai(Brigham and Women's Hospital), Jonathan G. Howlett(University of Calgary), Andrej Dukát(Copenhagen University Hospital), José Carlos Nicolau(Hospital São Paulo)
New England Journal of Medicine
September 19, 2019
Cited by 6,836


Related Papers